Ariad gets a green light for TKI study; Synergy files NDA;

@FierceBiotech: ICYMI Friday: Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen. Article | Follow @FierceBiotech

@JohnCFierce: Will Zika frenzy fuel an overnight vaccine R&D miracle? Don't bet on it. More | Follow @JohnCFierce

@DamianFierce: this man missed a huge opportunity in orthopedics. More from STAT | Follow @DamianFierce

> Cambridge, MA-based Ariad ($ARIA) says it has received FDA approval to launch a Phase I/II study of AP32788, a tyrosine kinase inhibitor for non-small cell lung cancer with specific mutations in EGFR or HER2. Release

> Synergy Pharmaceuticals ($SGYP) says it filed its first NDA, shooting for an approval of plecanatide in chronic idiopathic constipation. Report

> Exelixis' ($EXEL) kidney cancer treatment cabozantinib improved overall survival compared with everolimus in a Phase III trial, the company said. The drug is up for a final FDA decision by June 22. More

Medical Device News

@FierceMedDev: ICYMI: Philips taps transportation exec in its effort to industrialize, personalize healthcare. Article | Follow @FierceMedDev

@VarunSaxena2: Which pharma character is #1? FiercePharmaMarketing report | Follow @VarunSaxena2

@EmilyWFierce: Abbott inks $5.8B deal for Alere to expand in point-of-care diagnostics. Report | Follow @EmilyWFierce

> Smith & Nephew reveals its CEO has cancer, says he will remain in charge during treatment. News

> Stryker to buy disposable device maker for $2.7B to reduce hospital-acquired infections. Article

Pharma News

@FiercePharma: Lilly closes two animal health factories, citing no 'competitive business model.' FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Novartis is revamping its manufacturing after having disposed of 25 plants. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie. Article | Follow @CarlyHFierce

> Novartis braces for multibillion-dollar generics hit as Gleevec copies launch. Article

> Was Allergan's CEO simply touting a Texas plant expansion--or nudging watchdogs on Pfizer merger, too? More

> Roche sees no 'short term' pricing pressure for company's cancer drugs: Reuters. Story

Animal Health News

> Lilly closes two animal health factories, citing no 'competitive business model.' More

> IDEXX and Abaxis trade fortunes on Wall Street as earnings surprise investors. Story

> Merial teams with Georgia Tech to advance connected networks for animal health. Article

> Dog flu sweeps the U.S. with two more confirmed cases in Washington state. Report

> Aratana shares soar on first FDA filing for approval of canine arthritis drug. News

Biotech IT News

> CosmosID raises $6M to advance microbiome bioinformatics offering. Story

> BioClinica rolls out tech-enabled postapproval research service. Item

> DNAnexus connects genomics platform to Sapio Sciences' LIMS. More

> AstraZeneca taps CRISPR to extract value from genome data. Report

> Leo Pharma mounts $70M push into digital health technology. Article

Pharma Marketing News

> More link think? OPDP lists social media links as guidance item for 2016. Report

> Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says. Story

> Novo's Tresiba scores data for a new edge in insulin fight against Sanofi. Article

> Roche's pharma chief sees no 'short term' pricing pressure on its cancer blockbusters. More

> Novartis retrains Entresto reps, plans field force expansion as payers finally step up. Report